Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study - PubMed
6 hours ago
- #nimodipine
- #migraine
- #vestibular-migraine
- Study evaluates nimodipine and topiramate efficacy in treating migraine and vestibular migraine.
- Prospective multicenter open-label study in South Korea with 850 patients (81% women, mean age 41).
- Primary outcome: reduction in headache days over three months.
- Secondary outcomes: improvements in pain rating, MIDAS, HIT-6, dizziness days, and intensity.
- 465 patients completed the study (nimodipine: 205, topiramate: 160, combination: 100).
- All groups showed significant reduction in headache days (1.2-2 days/week, p < 0.001).
- Topiramate group had better MIDAS and HIT-6 improvements than nimodipine and combination groups.
- Vestibular migraine patients (n=131) improved in headache and dizziness outcomes (p < 0.001).
- Low adverse events (2% discontinuation rate), no significant differences among groups.
- Nimodipine is a valuable, well-tolerated option for migraine and vestibular migraine.